Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Mallinckrodt plc stock logo
MNK
Mallinckrodt
$0.34
$0.75
$6.42
$1.58MN/A2.62 million shs39,227 shs
Merus N.V. stock logo
MRUS
Merus
$55.11
+1.1%
$50.55
$33.19
$62.98
$3.77B1737,445 shs695,442 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.40
-1.3%
$3.53
$2.28
$6.71
$565.77M1.71.14 million shs636,975 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00%0.00%0.00%0.00%0.00%
Merus N.V. stock logo
MRUS
Merus
+1.10%+2.36%-2.37%+31.31%-1.27%
Organogenesis stock logo
ORGO
Organogenesis
-1.35%+1.15%+26.80%+3.29%+53.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
2.2055 of 5 stars
3.61.00.00.02.52.50.0
Organogenesis stock logo
ORGO
Organogenesis
4.3032 of 5 stars
3.03.00.04.31.34.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00
N/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00
N/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6453.58% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0036.36% Upside

Current Analyst Ratings Breakdown

Latest KIN, MRUS, MNK, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
4/28/2025
Merus N.V. stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/A$47.48 per shareN/A
Merus N.V. stock logo
MRUS
Merus
$36.13M105.57N/AN/A$9.46 per share5.83
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.16$0.21 per share21.37$2.09 per share2.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/A
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)

Latest KIN, MRUS, MNK, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Mallinckrodt plc stock logo
MNK
Mallinckrodt
1.18
0.57
0.31
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67

Institutional Ownership

CompanyInstitutional Ownership
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
83.74%
Merus N.V. stock logo
MRUS
Merus
96.14%
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.30%
Merus N.V. stock logo
MRUS
Merus
4.57%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Mallinckrodt plc stock logo
MNK
Mallinckrodt
2,70013.17 million13.13 millionNot Optionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable

Recent News About These Companies

Organogenesis Holdings Inc. (ORGO) - Yahoo Finance
CMS reviewing coverage policies for skin substitute products

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Kindred Biosciences stock logo

Kindred Biosciences NASDAQ:KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Mallinckrodt stock logo

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Merus stock logo

Merus NASDAQ:MRUS

$55.11 +0.60 (+1.10%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$55.10 -0.01 (-0.02%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.40 -0.06 (-1.35%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.40 +0.00 (+0.11%)
As of 07:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.